Stem cell therapy alleviates hair loss caused by COVID-19 vaccination

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

A case of a female patient with hair loss induced by coronavirus disease 2019 (COVID-19) vaccination who was treated with autologous CD34+ enriched hematopoietic progenitor cell fraction (CD34+ HPCF) and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs) was reported. The patient presented with generalized pain and hair loss after COVID-19 vaccination. The patient received subcutaneous injections of autologous CD34+ HPCF at 1-cm intervals into the scalp. These injections were administered once a week for a total of 10 times, except in weeks 5 and 10. During this period, UC-MSCs were administered intravenously at dose of 7×10 7 cells in 20 mL and subcutaneously at a dose of 1×10 7 cells in 5 mL into the scalp twice each in weeks 5 and 10. After 12 weeks of treatment, the patient's hair loss improved without significant adverse effects. Autologous CD34+ HPCF and UC-MSC injections showed significant effects on hair loss induced by COVID-19 vaccination.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.